Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386822 | 0.92 | GRM2 (0.35) | TMEM97SIGMAR1PKMPKLRNPSR1 | |
| SCHEMBL3989585 | 0.87 | PKM (0.35) | TMEM97SIGMAR1PKMPKLRNPSR1 | |
| SCHEMBL1383893 | 0.84 | PKM (0.37) | TMEM97SIGMAR1PKMPKLRNPSR1 | |
| SCHEMBL3985794 | 0.84 | PKM (0.37) | TMEM97SIGMAR1PKMPKLRADRA1A | |
| SCHEMBL3987278 | 0.84 | L3MBTL1 (0.34) | TMEM97SIGMAR1PKMPKLRNPSR1 | |
| SCHEMBL3988987 | 0.83 | PKM (0.31) | PKMPKLRNPSR1 | |
| SCHEMBL3985379 | 0.82 | PKM (0.35) | TMEM97SIGMAR1PKMPKLRNPSR1 | |
| SCHEMBL3985851 | 0.81 | KCNH2 (0.36) | TMEM97SIGMAR1PKMPKLR | |
| SCHEMBL1385524 | 0.81 | CNR2 (0.40) | SIGMAR1PKMPKLR | |
| SCHEMBL3984969 | 0.81 | PKM (0.38) | TMEM97SIGMAR1PKMPKLRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4824673-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1756114-A2 | HIV INTEGRASE INHIBITORS | Merck and Co., Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005110414-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1756114-A2 | HIV INTEGRASE INHIBITORS | Merck and Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005110414-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | TMEM97 2707/4885SIGMAR1 1891/4885PKM 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.